Accelerometry for remote monitoring of physical activity in amyotrophic lateral sclerosis: a longitudinal cohort study

被引:40
作者
van Eijk, Ruben P. A. [1 ,2 ]
Bakers, Jaap N. E. [3 ]
Bunte, Tommy M. [1 ]
de Fockert, Arianne J. [1 ]
Eijkemans, Marinus J. C. [2 ]
van den Berg, Leonard H. [1 ]
机构
[1] Univ Med Ctr Utrecht, Brain Ctr Rudolf Magnus, Dept Neurol, Heidelberglaan 100, NL-3584 CX Utrecht, Netherlands
[2] Univ Med Ctr Utrecht, Julius Ctr Hlth Sci & Primary Care, Biostat & Res Support, Utrecht, Netherlands
[3] Univ Med Ctr Utrecht, Brain Ctr Rudolf Magnus, Dept Rehabil, Utrecht, Netherlands
关键词
Amyotrophic lateral sclerosis; Accelerometry; Clinical trial; Longitudinal cohort study; ALS CLINICAL-TRIALS; PROGRESSION; SURVIVAL; TIME;
D O I
10.1007/s00415-019-09427-5
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background The extensive heterogeneity between patients with amyotrophic lateral sclerosis (ALS) complicates the quantification of disease progression. In this study, we determine the value of remote, accelerometer-based monitoring of physical activity in patients with ALS. Methods This longitudinal cohort study was conducted in a home-based setting; all study materials were sent by mail. Patients wore the ActiGraph during waking hours for 7 days every 2-3 months and provided information regarding their daily functioning (ALSFRS-R). We defined four accelerometer-based endpoints that either reflect the average daily activity or quantify the patient's physical capacity. Results A total of 42 patients participated; the total valid monitoring period was 9288 h with a 93.0% adherence rate. At baseline, patients were active 27.9% (range 11.6-52.4%) of their time; this declined by 0.64% (95% 0.43-0.86, p < 0.001) per month. Accelerometer-based endpoints were strongly associated with the ALSFRS-R (r 0.78, 95% CI 0.63-0.92, p < 0.001), but showed less variability over time than the ALSFRS-R (coefficient of variation 0.64-0.81 vs. 1.06, respectively). Accelerometer-based endpoints could reduce sample size by 30.3% for 12-month trials and 44.6% for 18-month trials; for trials lasting less than 9 months, the ALSFRS-R resulted in smaller sample sizes. Conclusion Accelerometry is an objective method for quantifying disease progression, which could obtain real-world insights in the patient's physical functioning and may personalize the delivery of care. In addition, remote monitoring provides patients with the opportunity to participate in clinical trials from home, paving the way to a patient-centric clinical trial model.
引用
收藏
页码:2387 / 2395
页数:9
相关论文
共 50 条
  • [21] Longitudinal Timed Up and Go Assessment in Amyotrophic Lateral Sclerosis: A Pilot Study
    Sukockiene, Egle
    Ferfoglia, Ruxandra Iancu
    Poncet, Antoine
    Janssens, Jean-Paul
    Allali, Gilles
    EUROPEAN NEUROLOGY, 2021, 84 (05) : 375 - 379
  • [22] Characteristics of Late-Onset Amyotrophic Lateral Sclerosis in a Chinese Cohort
    Sun, Qionghua
    Huo, Yunyun
    Bai, Jiongming
    Wang, Haoran
    Cui, Fang
    Wang, Hongfen
    Yang, Fei
    Huang, Xusheng
    NEURODEGENERATIVE DISEASES, 2021, 21 (1-2) : 24 - 29
  • [23] Coordinated care affects hospitalization and prognosis in amyotrophic lateral sclerosis: a cohort study
    Cordesse, Valerie
    Sidorok, Florence
    Schimmel, Priscilla
    Holstein, Josiane
    Meininger, Vincent
    BMC HEALTH SERVICES RESEARCH, 2015, 15
  • [24] Autonomic dysfunction is associated with disease progression and survival in amyotrophic lateral sclerosis: a prospective longitudinal cohort study
    Dubbioso, Raffaele
    Provitera, Vincenzo
    Pacella, Daniela
    Santoro, Lucio
    Manganelli, Fiore
    Nolano, Maria
    JOURNAL OF NEUROLOGY, 2023, 270 (10) : 4968 - 4977
  • [25] Autonomic dysfunction is associated with disease progression and survival in amyotrophic lateral sclerosis: a prospective longitudinal cohort study
    Raffaele Dubbioso
    Vincenzo Provitera
    Daniela Pacella
    Lucio Santoro
    Fiore Manganelli
    Maria Nolano
    Journal of Neurology, 2023, 270 : 4968 - 4977
  • [26] Experiences with advance care planning in amyotrophic lateral sclerosis: Qualitative longitudinal study with people with amyotrophic lateral sclerosis and their family carers
    Vandenbogaerde, Isabel
    Van den Block, Lieve
    Deliens, Luc
    Carduff, Emma
    van der Heide, Agnes
    De Bleecker, Jan
    De Vleminck, Aline
    PALLIATIVE MEDICINE, 2024, 38 (05) : 572 - 581
  • [27] Longitudinal Study of Cognitive and Emotional Alterations in Amyotrophic Lateral Sclerosis: Clinical and Imaging Data
    Benbrika, Soumia
    Doidy, Franck
    Carluer, Laurence
    Mondou, Audrey
    Pelerin, Alice
    Eustache, Francis
    Viader, Fausto
    Desgranges, Beatrice
    FRONTIERS IN NEUROLOGY, 2021, 12
  • [28] Multidisciplinary care in amyotrophic lateral sclerosis: a 4-year longitudinal observational study
    Egle, Sukockiene
    Ruxandra, Iancu Ferfoglia
    Andre, Truffert
    Anne-Chantal, Heritier Barras
    Laurence, Genton
    Valerie, Viatte
    Igor, Leuchter
    Monica, Escher
    Ninon, Horie
    Antoine, Poncet
    Patrick, Pasquina
    Dan, Adler
    Jean-Paul, Janssens
    SWISS MEDICAL WEEKLY, 2020, 150
  • [29] Longitudinal analysis of glymphatic function in amyotrophic lateral sclerosis and primary lateral sclerosis
    Sharkey, Rachel J.
    Cortese, Filomeno
    Goodyear, Bradley G.
    Korngut, Lawrence W.
    Jacob, Sarah M.
    Sharkey, Keith A.
    Kalra, Sanjay
    Nguyen, Minh Dang
    Frayne, Richard
    Pfeffer, Gerald
    BRAIN, 2024, 147 (12) : 4026 - 4032
  • [30] Decline of cognitive and behavioral functions in amyotrophic lateral sclerosis: a longitudinal study
    Bersano, Enrica
    Sarnelli, Maria Francesca
    Solara, Valentina
    Iazzolino, Barbara
    Peotta, Laura
    De Marchi, Fabiola
    Facchin, Alessio P.
    Moglia, Cristina
    Canosa, Antonio
    Calvo, Andrea
    Chio, Adriano
    Mazzini, Letizia
    AMYOTROPHIC LATERAL SCLEROSIS AND FRONTOTEMPORAL DEGENERATION, 2020, 21 (5-6) : 373 - 379